Canadian Active Drug Post Marketing Observational Epidemiological Study : Assessing an Active Drug Real-life Effectiveness and Impact on HS Burden of Illness

Brief summary

This study assesses an active drug real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).

Observational study

Hidradenitis Suppurativa (HS)
165 patients
Protocol ID:
Observational model:
Time perspective:


Eligibility criteria

Participant attributes:
Male and Female


From 18 Years to 99 Years.

Inclusion Criteria:

- Has a clinical diagnosis of moderate to severe HS according to the treating physician

- Need a change in ongoing therapy for any reason, but not limited to inadequate
response, intolerance, sub-optimal compliance, or patient preference. Patient will be
approached to participate in the study after a decision to change patient's therapy
for Humira® is made by the treating physician.

- Has provided written informed consent (Patient Authorization) for participation in the

Exclusion Criteria:

- Is participating in a clinical interventional study

- Was treated with Humira®, or any other biologic agents for HS prior to baseline visit

- Has any other active skin disease or condition that, in the opinion of the treating
physician, prohibits the patient from participating in the study or obscures the
assessment of the treatment of HS

All the cities where the clinical studies are located

Calgary - T3A 2N1
Edmonton - T6G 1C3
St. John's - A1A 4Y3
St. John's - A1C 2H5
St. John's - A1E 1V4
Halifax - B3H 1Z2
Barrie - L4M 7G1
London - N6H 5L5
Markham - L3P 1X2
Peterborough - K9J 5K2
Quebec - M5C1R6
Richmond Hill - L4C 9M7
Toronto - M2M 4J5
Quebec - M5C1R6
Waterloo - N2J 1C4
Drummondville - J2B 5L4
Laval - H7N 6L2
St-Jerome - J7Z 7E2
Verdun - H4G 3E7
Fredericton - E3B 1G9
Brandon - R7A 0L5
Winnipeg - R3C 1T6
Winnipeg - R3M 3Z4

More information about this study